Site | Number* of Cases | Percent of Total Cases | SEER** Summary Stage at Diagnosis | Race | Sex | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
In Situ | Local | Regional | Distant | Unstaged | White | African-American | Other | Male | Female | |||
All sites | 27,133 | 100.0% | 2,326 | 11,192 | 6,210 | 5,175 | 2,230 | 25,182 | 1,772 | 118 | 12,719 | 14,414 |
Oral cavity and pharynx | 601 | 2.2% | 9 | 244 | 282 | 34 | 32 | 554 | 42 | 4 | 427 | 174 |
Lip | 57 | 0.2% | 1 | 49 | 3 | 1 | 3 | 56 | 1 | 0 | 50 | 7 |
Tongue | 133 | 0.5% | 1 | 51 | 68 | 5 | 8 | 119 | 14 | 0 | 86 | 47 |
Major salivary glands | 65 | 0.2% | 0 | 29 | 26 | 5 | 5 | 57 | 7 | 1 | 40 | 25 |
Floor of mouth | 67 | 0.2% | 6 | 34 | 24 | 1 | 2 | 62 | 5 | 0 | 51 | 16 |
Gum and other mouth | 95 | 0.4% | 0 | 48 | 39 | 5 | 3 | 93 | 1 | 0 | 59 | 36 |
Nasopharynx | 29 | 0.1% | 0 | 2 | 21 | 1 | 5 | 25 | 2 | 2 | 18 | 11 |
Tonsil | 79 | 0.3% | 1 | 10 | 59 | 7 | 2 | 72 | 7 | 0 | 64 | 15 |
Oropharynx | 24 | 0.1% | 0 | 5 | 13 | 3 | 3 | 22 | 2 | 0 | 21 | 3 |
Hypopharynx | 35 | 0.1% | 0 | 11 | 19 | 4 | 1 | 31 | 3 | 1 | 28 | 7 |
Pharynx and other oral cavity | 17 | 0.1% | 0 | 5 | 10 | 2 | 0 | 17 | 0 | 0 | 10 | 7 |
Digestive system | 5,070 | 18.7% | 263 | 1,394 | 1,962 | 1,062 | 389 | 4,664 | 376 | 25 | 2,539 | 2,531 |
Esophagus | 237 | 0.9% | 5 | 60 | 81 | 65 | 26 | 213 | 21 | 2 | 190 | 47 |
Stomach | 351 | 1.3% | 4 | 74 | 143 | 87 | 43 | 300 | 45 | 6 | 210 | 141 |
Small intestine | 94 | 0.3% | 1 | 21 | 40 | 18 | 14 | 80 | 14 | 0 | 39 | 55 |
Colon excluding rectum | 2,455 | 9.0% | 156 | 735 | 1,048 | 421 | 95 | 2,282 | 163 | 7 | 1,121 | 1,334 |
Rectum and rectosigmoid | 987 | 3.6% | 84 | 326 | 348 | 160 | 69 | 937 | 46 | 3 | 519 | 468 |
Anus, anal canal, and anorectum | 90 | 0.3% | 9 | 42 | 20 | 13 | 6 | 85 | 4 | 1 | 31 | 59 |
Liver and intrahepatic bile duct | 141 | 0.5% | 0 | 40 | 26 | 42 | 33 | 118 | 21 | 2 | 97 | 44 |
Gallbladder | 80 | 0.3% | 3 | 24 | 27 | 24 | 2 | 74 | 5 | 1 | 22 | 58 |
Other biliary | 74 | 0.3% | 1 | 18 | 31 | 5 | 19 | 67 | 7 | 0 | 43 | 31 |
Pancreas | 495 | 1.8% | 0 | 46 | 190 | 197 | 62 | 446 | 46 | 3 | 247 | 248 |
Retroperitoneum | 21 | 0.1% | 0 | 8 | 4 | 3 | 6 | 19 | 2 | 0 | 9 | 12 |
Peritoneum | 28 | 0.1% | 0 | 0 | 3 | 19 | 6 | 28 | 0 | 0 | 4 | 24 |
Other digestive organs | 17 | 0.1% | 0 | 0 | 1 | 8 | 8 | 15 | 2 | 0 | 7 | 10 |
Respiratory system | 4,714 | 17.4% | 23 | 1,149 | 1,364 | 1,819 | 359 | 4,351 | 348 | 12 | 2,854 | 1,860 |
Nasal cavity, ear, and sinuses | 38 | 0.1% | 0 | 9 | 17 | 7 | 5 | 33 | 4 | 0 | 23 | 15 |
Larynx | 312 | 1.1% | 14 | 182 | 98 | 9 | 9 | 283 | 29 | 0 | 224 | 88 |
Lung and bronchus | 4,311 | 15.9% | 9 | 944 | 1,225 | 1,796 | 337 | 3,982 | 315 | 12 | 2,562 | 1,749 |
Trachea, pleura, and other respiratory organs | 53 | 0.2% | 0 | 14 | 24 | 7 | 8 | 53 | 0 | 0 | 45 | 8 |
Bones and joints | 55 | 0.2% | 0 | 20 | 19 | 6 | 10 | 52 | 3 | 0 | 31 | 24 |
Soft tissue (including heart) | 144 | 0.5% | 0 | 88 | 18 | 23 | 15 | 137 | 7 | 0 | 79 | 65 |
Skin (excluding basal and squamous) | 884 | 3.3% | 126 | 606 | 51 | 35 | 66 | 860 | 6 | 0 | 505 | 379 |
Melanoma of the skin | 827 | 3.0% | 123 | 564 | 45 | 32 | 63 | 805 | 5 | 0 | 469 | 358 |
Other non-epithelial skin cancers | 57 | 0.2% | 3 | 42 | 6 | 3 | 3 | 55 | 1 | 0 | 36 | 21 |
Breast | 4,558 | 16.8% | 675 | 2,460 | 1,124 | 199 | 100 | 4,255 | 278 | 22 | 26 | 4,532 |
Female genital system | 2,551 | 9.4% | 810 | 998 | 321 | 350 | 72 | 2,377 | 151 | 18 | 0 | 2,551 |
Cervix uteri | 994 | 3.7% | 681 | 165 | 105 | 28 | 15 | 895 | 81 | 13 | 0 | 994 |
Corpus uteri | 836 | 3.1% | 23 | 624 | 107 | 60 | 22 | 800 | 34 | 2 | 0 | 836 |
Uterus, NOS | 12 | 0.0% | 0 | 7 | 2 | 2 | 1 | 12 | 0 | 0 | 0 | 12 |
Ovary | 488 | 1.8% | 2 | 142 | 79 | 247 | 18 | 459 | 27 | 2 | 0 | 488 |
Vagina | 35 | 0.1% | 10 | 5 | 13 | 5 | 2 | 33 | 1 | 1 | 0 | 35 |
Vulva | 171 | 0.6% | 94 | 53 | 14 | 3 | 7 | 164 | 7 | 0 | 0 | 171 |
Other female genital organs | 15 | 0.1% | 0 | 2 | 1 | 5 | 7 | 14 | 1 | 0 | 0 | 15 |
Male genital system | 3,220 | 11.9% | 17 | 2,343 | 404 | 186 | 270 | 2,919 | 278 | 14 | 3,220 | 0 |
Prostate gland | 3,047 | 11.2% | 7 | 2,230 | 376 | 169 | 265 | 2,754 | 274 | 10 | 3,047 | 0 |
Testis | 133 | 0.5% | 0 | 88 | 25 | 16 | 4 | 128 | 1 | 4 | 133 | 0 |
Penis | 37 | 0.1% | 10 | 24 | 2 | 0 | 1 | 34 | 3 | 0 | 37 | 0 |
Other male genital organs | 3 | 0.0% | 0 | 1 | 1 | 1 | 0 | 3 | 0 | 0 | 3 | 0 |
Urinary system | 1,956 | 7.2% | 403 | 1,007 | 255 | 206 | 85 | 1,870 | 78 | 4 | 1,326 | 630 |
Urinary bladder | 1,194 | 4.4% | 383 | 623 | 113 | 31 | 44 | 1,152 | 37 | 1 | 869 | 325 |
Kidney and renal pelvis | 701 | 2.6% | 6 | 355 | 131 | 171 | 38 | 660 | 38 | 3 | 421 | 280 |
Ureter | 44 | 0.2% | 10 | 23 | 9 | 2 | 0 | 43 | 1 | 0 | 25 | 19 |
Other urinary organs | 17 | 0.1% | 4 | 6 | 2 | 2 | 3 | 15 | 2 | 0 | 11 | 6 |
Eye and orbit | 57 | 0.2% | 0 | 48 | 3 | 1 | 5 | 54 | 1 | 1 | 36 | 21 |
Brain and other nervous system | 366 | 1.3% | 0 | 275 | 48 | 2 | 41 | 349 | 16 | 1 | 212 | 154 |
Brain | 349 | 1.3% | 0 | 265 | 45 | 2 | 37 | 334 | 14 | 1 | 203 | 146 |
Other nervous system | 17 | 0.1% | 0 | 10 | 3 | 0 | 4 | 15 | 2 | 0 | 9 | 8 |
Endocrine system | 311 | 1.1% | 0 | 187 | 93 | 18 | 13 | 290 | 17 | 4 | 91 | 220 |
Thyroid gland | 279 | 1.0% | 0 | 180 | 83 | 10 | 6 | 263 | 12 | 4 | 70 | 209 |
Other endocrine (including thymus) | 32 | 0.1% | 0 | 7 | 10 | 8 | 7 | 27 | 5 | 0 | 21 | 11 |
Lymphoma | 1,163 | 4.3% | 0 | 362 | 266 | 385 | 150 | 1,099 | 52 | 7 | 603 | 560 |
Hodgkin's disease | 168 | 0.6% | 0 | 43 | 79 | 31 | 15 | 156 | 11 | 1 | 93 | 75 |
Non-Hodgkin's lymphoma | 995 | 3.7% | 0 | 319 | 187 | 354 | 135 | 943 | 41 | 6 | 510 | 485 |
Multiple myeloma | 290 | 1.1% | 0 | 10 | 0 | 279 | 1 | 247 | 41 | 1 | 140 | 150 |
Leukemia | 560 | 2.1% | 0 | 0 | 0 | 560 | 0 | 525 | 28 | 4 | 307 | 253 |
Acute lymphocytic | 72 | 0.3% | 0 | 0 | 0 | 72 | 0 | 70 | 1 | 1 | 42 | 30 |
Chronic lymphocytic | 135 | 0.5% | 0 | 0 | 0 | 135 | 0 | 129 | 6 | 0 | 83 | 52 |
Acute myeloid | 186 | 0.7% | 0 | 0 | 0 | 186 | 0 | 172 | 11 | 3 | 90 | 96 |
Chronic myeloid | 81 | 0.3% | 0 | 0 | 0 | 81 | 0 | 71 | 8 | 0 | 46 | 35 |
Other leukemias | 86 | 0.3% | 0 | 0 | 0 | 86 | 0 | 83 | 2 | 0 | 46 | 40 |
Other, ill-defined and unknown sites | 633 | 2.3% | 0 | 1 | 0 | 10 | 622 | 579 | 50 | 1 | 323 | 310 |
* Please note that these totals will not match those in Table VII - 0 as these numbers include all in situ cases, though basal and squamous skin cell cancers are still excluded. ** Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Source : Indiana State Department of Health - Indiana State Cancer Registry and the Epidemiology Resource Center, Data Analysis Team, January 2003 |